{"entity":{"id":"nct07419295","kind":"trial","name":"A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)","aka":["TroFuse-031"],"tldr":"A phase 3 trial of Sacituzumab tirumotecan, Vinflunine and Docetaxel in bladder & urothelial cancer, run by Merck Sharp & Dohme LLC, now recruiting.","summary":"A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031) is a phase 3 interventional study registered as NCT07419295 by Merck Sharp & Dohme LLC, with 590 participants planned, started 2026-04-23 and due to reach its primary completion in 2029-07-27. Interventions recorded: Sacituzumab tirumotecan, Vinflunine, Docetaxel, Paclitaxel, Rescue medications for sacituzumab tirumotecan and Rescue medications for chemotherapy.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07419295","url":"https://clinicaltrials.gov/study/NCT07419295"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["urothelial","muscle-invasive-bladder-cancer"],"sections":[],"technologies":["adc","topoisomerase-inhibitors"],"targets":[],"drugs":["sacituzumab-tirumotecan","vinflunine","docetaxel"],"companies":["merck"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07419295","phase":"3","setting":"A Phase 3, Randomized, Open-label Study of Sacituzumab Tirumotecan (MK-2870) Versus Investigator's Choice of Non-platinum Chemotherapy in Participants With Pretreated Locally Advanced/Metastatic Urothelial Carcinoma","sponsor":"Merck Sharp & Dohme LLC","participation":[{"nct":"NCT07419295","source":"https://clinicaltrials.gov/study/NCT07419295","fetchedAt":"2026-10-07T16:55:44.977Z","studySha256":"8be6dc3e51d83d55fd16560d8f4fe1bde6a08a25293b57dd5c5935ec0c9d9569","overallStatus":"RECRUITING","lastUpdatePosted":"2026-10-06","leadSponsor":"Merck Sharp & Dohme LLC","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":590,"enrolmentType":"ESTIMATED","siteCount":104,"recruitingSiteCount":104,"countries":["Argentina","Australia","Belgium","Brazil","Canada","China","France","Germany","Greece","Israel","Italy","Japan","Netherlands","Spain","Sweden","United Kingdom","United States"]}],"started":"2026-04-23","startedType":"actual","enrolled":590,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07419295/","neighbours":{"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"},{"id":"muscle-invasive-bladder-cancer","kind":"cancer","name":"Muscle-invasive and advanced bladder cancer","route":"/cancers/muscle-invasive-bladder-cancer/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"topoisomerase-inhibitors","kind":"technology","name":"Topoisomerase-I inhibitors (and ADC payloads)","route":"/technologies/topoisomerase-inhibitors/"}],"drug":[{"id":"docetaxel","kind":"drug","name":"Docetaxel","route":"/drugs/docetaxel/"},{"id":"sacituzumab-tirumotecan","kind":"drug","name":"Sacituzumab tirumotecan","route":"/drugs/sacituzumab-tirumotecan/"},{"id":"vinflunine","kind":"drug","name":"Vinflunine","route":"/drugs/vinflunine/"}],"company":[{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/"}]}}